Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
83.85
-2.83 (-3.26%)
At close: Apr 28, 2026, 4:00 PM EDT
83.83
-0.02 (-0.03%)
After-hours: Apr 28, 2026, 7:20 PM EDT
Kymera Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 39.21 | 47.07 | 78.59 | 46.83 | 72.83 | |
| Revenue Growth (YoY) | -16.70% | -40.11% | 67.84% | -35.71% | 114.00% | |
| Cost of Revenue | 316.57 | 240.25 | 189.08 | 164.25 | 137.02 | |
| Gross Profit | -277.36 | -193.18 | -110.49 | -117.42 | -64.19 | |
| Selling, General & Admin | 68.19 | 63.53 | 55.04 | 43.83 | 36.35 | |
| Operating Expenses | 68.19 | 63.53 | 55.04 | 43.83 | 36.35 | |
| Operating Income | -345.54 | -256.71 | -165.53 | -161.26 | -100.53 | |
| Interest Expense | -0.37 | -0.25 | -0.2 | -0.18 | -0.18 | |
| Interest & Investment Income | 38.42 | 38.03 | 18.76 | 6.62 | 0.49 | |
| EBT Excluding Unusual Items | -307.5 | -218.93 | -146.96 | -154.81 | -100.22 | |
| Asset Writedown | -3.86 | -4.93 | - | - | - | |
| Pretax Income | -311.35 | -223.86 | -146.96 | -154.81 | -100.22 | |
| Net Income | -311.35 | -223.86 | -146.96 | -154.81 | -100.22 | |
| Net Income to Common | -311.35 | -223.86 | -146.96 | -154.81 | -100.22 | |
| Shares Outstanding (Basic) | 84 | 75 | 58 | 54 | 48 | |
| Shares Outstanding (Diluted) | 84 | 75 | 58 | 54 | 48 | |
| Shares Change (YoY) | 12.59% | 28.58% | 8.22% | 12.39% | 176.60% | |
| EPS (Basic) | -3.69 | -2.98 | -2.52 | -2.87 | -2.09 | |
| EPS (Diluted) | -3.69 | -2.98 | -2.52 | -2.87 | -2.09 | |
| Free Cash Flow | -234.34 | -207.34 | -137.31 | -155.92 | -130.54 | |
| Free Cash Flow Per Share | -2.77 | -2.76 | -2.35 | -2.89 | -2.72 | |
| Gross Margin | - | - | -140.59% | -250.76% | -88.13% | |
| Operating Margin | -881.24% | -545.36% | -210.62% | -344.37% | -138.03% | |
| Profit Margin | -794.04% | -475.56% | -186.99% | -330.60% | -137.60% | |
| Free Cash Flow Margin | -597.64% | -440.47% | -174.71% | -332.98% | -179.24% | |
| EBITDA | -338.83 | -250.74 | -163.47 | -159.48 | -99.03 | |
| EBITDA Margin | - | - | -207.99% | - | -135.97% | |
| D&A For EBITDA | 6.71 | 5.97 | 2.07 | 1.78 | 1.5 | |
| EBIT | -345.54 | -256.71 | -165.53 | -161.26 | -100.53 | |
| EBIT Margin | - | - | -210.62% | - | -138.03% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.